SIC
HRTX icon

SJS Investment Consulting’s Heron Therapeutics HRTX Stock Holding History

SJS Investment Consulting’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178 Sell
415
-10
-2% -$8 ﹤0.01% 2499
2026
Q1 		$341 Buy
425
+25
+6% +$29 ﹤0.01% 1859
2025
Q4 		$520 Hold
400
– – ﹤0.01% 1508
2025
Q3 		$504 Hold
400
– – ﹤0.01% 1224
2025
Q2 		$828 Hold
400
– – ﹤0.01% 930
2025
Q1 		$880 Hold
400
– – ﹤0.01% 1044
2024
Q4 		$612 Hold
400
– – ﹤0.01% 1178
2024
Q3 		$796 Hold
400
– – ﹤0.01% 1148
2024
Q2 		$1.4K Hold
400
– – ﹤0.01% 889
2024
Q1 		$1.11K Buy
+400
New +$1K ﹤0.01% 1000

Other funds holding HRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SJS Investment Consulting's HRTX Position: Q2 2026 in Review

SJS Investment Consulting reduced its Heron Therapeutics (HRTX) stake by 2.4% in Q2 2026, selling an estimated $8 and leaving 415 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #2499.

SJS Investment Consulting first reported a position in HRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.4K in Q2 2024. 76 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • SJS Investment Consulting held 415 shares of Heron Therapeutics worth $178 as of Q2 2026.
  • SJS Investment Consulting sold 10 Heron Therapeutics shares in Q2 2026, an estimated $8.
  • Heron Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2499 holding.
  • SJS Investment Consulting first reported a position in Heron Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • SJS Investment Consulting's Heron Therapeutics position peaked at $1.4K in Q2 2024.
  • 76 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.